secwatch.observer — SEC 8-K summary
======================================

Issuer:     iBio, Inc. (IBIO)
CIK:        0001420720
Form:       8-K
Filed at:   2026-08-28T12:30:48+00:00
Accession:  0001420720-26-000019
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

iBio FY2026: cash $88M, R&D up to $19.6M, IBIO-600 Phase 1 on track
-------------------------------------------------------------------

- Revenue $0.1M (down from $0.4M); R&D expenses $19.6M vs $8.3M; G&A $10.6M.
- Cash and investments $88.0M as of June 30, 2026; runway extended into FY2028.
- IBIO-600 Phase 1 dosed 31 of 32 participants; advancing to multiple ascending dose.
- IBIO-610 and IBIO-800 in IND-enabling studies; in-licensed AstralBio amylin receptor program.
- Financings: $100M public offering (Aug 2025), $26M private placement (Jan 2026), $100M ATM with Jefferies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420720/000142072026000019/0001420720-26-000019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420720/000142072026000019/ibio-20260828x8k.htm
  HTML page:      https://secwatch.observer/filing/0001420720-26-000019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer